Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis—United States, 2018

17Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Vulvovaginal candidiasis (VVC) is a common cause of vaginitis, but the national burden is unknown, and clinical diagnosis without diagnostic testing is often inaccurate. We aimed to calculate rates and evaluate diagnosis and treatment practices of VVC and recurrent vulvovaginal candidiasis (RVVC) in the United States. We used the 2018 IBM® MarketScan® Research Databases, which include health insurance claims data on outpatient visits and prescriptions for >28 million people. We used diagnosis and procedure codes to examine underlying conditions, vaginitis-related symptoms and conditions, diagnostic testing, and antibacterial and antifungal treatment among female patients with VVC. Among 12.3 million female patients in MarketScan, 149,934 (1.2%) had a diagnosis code for VVC; of those, 3.4% had RVVC. The VVC rate was highest in the South census region (14.3 per 1,000 female patients) and lowest in the West (9.9 per 1000). Over 60% of patients with VVC did not have codes for any diagnostic testing, and microscopy was the most common test type performed in 29.5%. Higher rates of diagnostic testing occurred among patients who visited an OB/GYN (53.4%) compared with a family practice or internal medicine provider (24.2%) or other healthcare provider types (31.9%); diagnostic testing rates were lowest in the South (34.0%) and highest in the Midwest (41.0%). Treatments on or in the 7 days after diagnosis included systemic fluconazole (70.0%), topical antifungal medications (19.4%), and systemic antibacterial medications (17.2%). The low frequencies of diagnostic testing for VVC and high rates of antifungal and antibacterial use suggest substantial empiric treatment, including likely overprescribing of antifungal medications and potentially unnecessary antibacterial medications. These findings support a need for improved clinical care for VVC to improve both patient outcomes and antimicrobial stewardship, particularly in the South and among non-OB/GYN providers.

References Powered by Scopus

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

2892Citations
N/AReaders
Get full text

Vulvovaginal candidosis

1094Citations
N/AReaders
Get full text

Recurrent vulvovaginal candidiasis

382Citations
N/AReaders
Get full text

Cited by Powered by Scopus

In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China

10Citations
N/AReaders
Get full text

Public Health Research Priorities for Fungal Diseases: A Multidisciplinary Approach to Save Lives

7Citations
N/AReaders
Get full text

Psychosocial impact of recurrent urogenital infections: a review

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Benedict, K., Lyman, M., & Jackson, B. R. (2022). Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis—United States, 2018. PLoS ONE, 17(4 April). https://doi.org/10.1371/journal.pone.0267866

Readers over time

‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

75%

Professor / Associate Prof. 1

13%

Lecturer / Post doc 1

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

67%

Biochemistry, Genetics and Molecular Bi... 1

11%

Nursing and Health Professions 1

11%

Pharmacology, Toxicology and Pharmaceut... 1

11%

Article Metrics

Tooltip
Mentions
News Mentions: 40

Save time finding and organizing research with Mendeley

Sign up for free
0